JP7710374B2 - 骨肉腫を治療するための組成物及び使用方法 - Google Patents

骨肉腫を治療するための組成物及び使用方法

Info

Publication number
JP7710374B2
JP7710374B2 JP2021550227A JP2021550227A JP7710374B2 JP 7710374 B2 JP7710374 B2 JP 7710374B2 JP 2021550227 A JP2021550227 A JP 2021550227A JP 2021550227 A JP2021550227 A JP 2021550227A JP 7710374 B2 JP7710374 B2 JP 7710374B2
Authority
JP
Japan
Prior art keywords
antibody
seq
sequence
antibodies
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021550227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522011A (ja
JP2022522011A5 (enExample
Inventor
ジェーン ジャン
マヌエル リケルメ
スミン グー
Original Assignee
ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム filed Critical ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム
Publication of JP2022522011A publication Critical patent/JP2022522011A/ja
Publication of JP2022522011A5 publication Critical patent/JP2022522011A5/ja
Application granted granted Critical
Publication of JP7710374B2 publication Critical patent/JP7710374B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021550227A 2019-02-28 2020-02-28 骨肉腫を治療するための組成物及び使用方法 Active JP7710374B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811938P 2019-02-28 2019-02-28
US62/811,938 2019-02-28
PCT/US2020/020343 WO2020176844A1 (en) 2019-02-28 2020-02-28 Compositions for treating osteosarcoma and methods of use

Publications (3)

Publication Number Publication Date
JP2022522011A JP2022522011A (ja) 2022-04-13
JP2022522011A5 JP2022522011A5 (enExample) 2023-03-07
JP7710374B2 true JP7710374B2 (ja) 2025-07-18

Family

ID=72238666

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021550227A Active JP7710374B2 (ja) 2019-02-28 2020-02-28 骨肉腫を治療するための組成物及び使用方法

Country Status (7)

Country Link
US (1) US20220162298A1 (enExample)
EP (1) EP3931222A4 (enExample)
JP (1) JP7710374B2 (enExample)
CN (2) CN113574070B (enExample)
AU (1) AU2020229374A1 (enExample)
CA (1) CA3131925A1 (enExample)
WO (1) WO2020176844A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4277928A4 (en) * 2021-01-13 2025-03-19 Board of Regents, The University of Texas System COMPOSITIONS AND METHODS FOR THE TREATMENT OF OSTEOARTHRITIS, RHEUMATOID ARTHRITIS AND JOINT AND TENDON DISEASES

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
WO2015027120A1 (en) 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
WO2017147561A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116854816A (zh) * 2018-04-02 2023-10-10 阿拉玛布治疗学股份有限公司 连接蛋白43抗体及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013091903A1 (en) 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
WO2015027120A1 (en) 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
WO2017147561A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF

Also Published As

Publication number Publication date
JP2022522011A (ja) 2022-04-13
AU2020229374A2 (en) 2021-10-21
EP3931222A1 (en) 2022-01-05
WO2020176844A1 (en) 2020-09-03
EP3931222A4 (en) 2023-11-01
AU2020229374A1 (en) 2021-08-19
CN113574070A (zh) 2021-10-29
CN119950706A (zh) 2025-05-09
CN113574070B (zh) 2025-02-25
CA3131925A1 (en) 2020-09-03
US20220162298A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
US12503500B2 (en) Connexin 43 (Cx43) hemichannel-binding antibodies
EP2970494B1 (en) Her3 specific monoclonal antibodies for diagnostic and therapeutic use
KR20170058960A (ko) Agr2 및 그의 수용체 c4.4a 에 대한 차단 모노클로날 항체
CN113574070B (zh) 用于治疗骨肉瘤的组合物和使用方法
US10759857B2 (en) JAM-C antibodies and methods for treatment of cancer
HK40062936B (en) Compositions for treating osteosarcoma and methods of use
HK40100475A (en) Connexin (cx)43 hemichannel-binding antibodies and uses thereof
HK40062936A (en) Compositions for treating osteosarcoma and methods of use
WO2025090760A1 (en) Antibodies specific to scube3 and methods of use
HK1262261B (en) Connexin (cx) 43 hemichannel-binding antibodies and uses thereof
HK1262261A1 (en) Connexin (cx) 43 hemichannel-binding antibodies and uses thereof
HK1213584B (en) Jam-c antibodies and methods for treatment of cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230227

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240716

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250708

R150 Certificate of patent or registration of utility model

Ref document number: 7710374

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150